Skip to content

Tectonic Therapeutics TECX Free cash flow yield

Free cash flow yield at other companies

ALN
Alnylam PharmaceuticalsALNY
1.5%+1.3pp
Septerna, Inc. logo
Septerna, Inc.SEPN
12.3%
Regenxbio logo
RegenxbioRGNX
-54.7%-272pp
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
0.5%
Opko Health logo
Opko HealthOPK
-20.1%+1.9pp
Ginkgo Bioworks logo
Ginkgo BioworksDNA
-44.3%-16.2pp

Other financials

Income statement

See full
Operating income-$27.3M-49.2%
Net income-$25.2M-58.7%
EPS (diluted)-$1.34-44.1%

Balance sheet

See full
Cash & equivalents$236.9M-22.8%
Total debt$4.9M+86.1%
Total equity$230.4M-23.5%
Total assets$246.6M-21.7%

Cash flow

See full
Operating cash flow-$18.4M-40.7%
CapEx$19.0K-29.6%
Free cash flow-$18.4M-40.6%

Valuation

See full
Market cap$585.51M+58.3%
Enterprise value$353.51M+438%

Returns & leverage

See full
Return on equity-31.4%
Debt / equity0.0×
Current ratio18.5×-4.4×

Where this comes from

Calculated from Tectonic Therapeutics’s reported figures.

Based on trailing twelve months.

The official record: Tectonic Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tectonic Therapeutics's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tectonic Therapeutics's free cash flow yield?
Tectonic Therapeutics (TECX) reported free cash flow yield of -11.3% in Q1 2026.
How has Tectonic Therapeutics's free cash flow yield changed year-over-year?
Tectonic Therapeutics's free cash flow yield increased by 40.8% year-over-year, from -19.1% to -11.3%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.